Glucagon-like peptide 1 receptor agonist (GLP-1 RA): Long-term effect on kidney function in patients with type 2 diabetes

Journal of Diabetes and its Complications

Volumn 29, Issue 5, 2015, Pages 670-674

  Von Scholten, Bernt Johan ^a   Hansen, Tine Willum ^a   Goetze, Jens Peter ^b,c   Persson, Frederik ^a   Rossing, Peter ^a,c,d  

^a STENO DIABETES CENTER   (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Glomerular filtration rate; GLP 1; Kidney function; Liraglutide; MR proANP; Urinary albumin excretion rate

Indexed keywords

ALBUMIN; EDETATE CHROMIUM CR 51; HEMOGLOBIN A1C; LIRAGLUTIDE; ANTIDIABETIC AGENT; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; AGED; AGONISTS; ALBUMINURIA; COMPLICATION; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; FOLLOW UP; HYPERGLYCEMIA; KIDNEY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY;

AGED; ALBUMINURIA; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; KIDNEY; LIRAGLUTIDE; MALE; MIDDLE AGED; RENAL INSUFFICIENCY;

EID: 84930572421     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2015.04.004     Document Type: Article

References (28)

1. A. Astrup, R. Carraro, N. Finer, A. Harper, M. Kunesova, and M.E. Lean Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide International Journal of Obesity 36 2012 843 854
2. R.M. Bergenstal, C. Wysham, and L. Macconell Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial Lancet 376 2010 431 439
3. J. Brochner-Mortensen A simple method for the determination of glomerular filtration rate Scandinavian Journal of Clinical and Laboratory Investigation 30 1972 271 274
4. R.V. Campos, Y.C. Lee, and D.J. Drucker Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse Endocrinology 134 1994 2156 2164
5. J.S. Christiansen, M. Frandsen, and H.H. Parving Effect of intravenous glucose infusion on renal function in normal man and in insulin-dependent diabetics Diabetologia 21 1981 368 373
6. R.O. Crajoinas, F.T. Oricchio, and T.D. Pessoa Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1 American Journal of Physiology. Renal Physiology 301 2011 F355 F363
7. J.A. Davidson, J. Brett, A. Falahati, and D. Scott Mild renal impairment and the efficacy and safety of liraglutide Endocrine Practice 17 2011 345 355
8. P.H. Groop, M.E. Cooper, V. Perkovic, A. Emser, H.J. Woerle, and E.M. von Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction Diabetes Care 36 2013 3460 3468
9. J.P. Gutzwiller, P. Hruz, and A.R. Huber Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans Digestion 73 2006 142 150
10. J.P. Gutzwiller, S. Tschopp, and A. Bock Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men Journal of Clinical Endocrinology and Metabolism 89 2004 3055 3061
11. I. Hunter, U. Alehagen, U. Dahlstrom, J.F. Rehfeld, D.L. Crimmins, and J.P. Goetze N-terminal pro-atrial natriuretic peptide measurement in plasma suggests covalent modification Clinical Chemistry 57 2011 1327 1330
12. S. Imamura, K. Hirai, and A. Hirai The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients Tohoku Journal of Experimental Medicine 231 2013 57 61
13. Y. Ishibashi, T. Matsui, and A. Ojima Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A Microvascular Research 84 2012 395 398
14. R. Kodera, K. Shikata, and H.U. Kataoka Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes Diabetologia 54 2011 965 978
15. M. Korner, M. Stockli, B. Waser, and J.C. Reubi GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting Journal of Nuclear Medicine 48 2007 736 743
16. A. Mima, J. Hiraoka-Yamomoto, and Q. Li Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes Diabetes 61 2012 2967 2979
17. N.G. Morgenthaler, J. Struck, B. Thomas, and A. Bergmann Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma Clinical Chemistry 50 2004 234 236
18. M.H. Muskiet, M.M. Smits, L.M. Morsink, and M. Diamant The gut-renal axis: Do incretin-based agents confer renoprotection in diabetes? Nature Reviews Nephrology 10 2014 88 103
19. M. Pawaskar, K.R. Tuttle, Q. Li, J.H. Best, and P.W. Anderson Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine Annals of Pharmacotherapy 48 2014 571 576
20. A. Pezeshki, G.P. Muench, and P.K. Chelikani Short communication: Expression of peptide YY, proglucagon, neuropeptide Y receptor Y2, and glucagon-like peptide-1 receptor in bovine peripheral tissues Journal of Dairy Science 95 2012 5089 5094
21. C. Pyke, R.S. Heller, and R.K. Kirk GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody Endocrinology 155 2014 1280 1290
22. P. Schlatter, C. Beglinger, J. Drewe, and H. Gutmann Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells Regulatory Peptides 141 2007 120 128
23. B.M. Scirica, D.L. Bhatt, and E. Braunwald Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus New England Journal of Medicine 369 2013 1317 1326
24. J. Skov, A. Dejgaard, and J. Frokiaer Glucagon-like peptide-1 (GLP-1): Effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men Journal of Clinical Endocrinology and Metabolism 98 2013 E664 E671
25. S. Theilade, C. Joergensen, F. Persson, M. Lajer, and P. Rossing Ambulatory tonometric blood pressure measurements in patients with diabetes Diabetes Technology & Therapeutics 14 2012 453 456
26. B.J. von Scholten, M. Lajer, J.P. Goetze, F. Persson, and P. Rossing Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment Diabetic Medicine 32 3 2015 343 352 10.1111/dme.12594
27. M. Zavattaro, M. Caputo, and M.T. Sama One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: A pilot prospective study Endocrine 2015 Jan 9 (Epub ahead of print)
28. H. Zhang, X. Zhang, C. Hu, and W. Lu Exenatide reduces urinary transforming growth factor-beta1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria Kidney and Blood Pressure Research 35 2012 483 488